Head-to-head · WeighScore
Henry Meds vs Immortals
The verdict
Henry Meds takes it — 77.3/100 to 61.8/100.
Henry Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A flat-fee compounded pioneer — simple, but priced at the higher end of the board now.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Henry Meds | Immortals |
|---|---|---|
| WeighScore | 77.3/100 | 61.8/100 |
| Grade | C+ | C |
| Scorecard rank | #46 | #286 |
| Semaglutide | $249/mo | $167/mo (microdose tier, compounded) |
| Tirzepatide | $349/mo | $180/mo (microdose tier, compounded) |
| Coverage | Multi-state | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #46 · C+
Strengths
- Simple flat-fee model
- Established brand
- Both molecules
Where it loses points
- Higher pricing than newer entrants
- Compounded only
Graded #286 · C
Strengths
- LegitScript certified (ID 50458743) with board-certified U.S. physician review within 72 hours
- Physician consult + prescription bundled in price — 'You pay for treatment. That's it' with no added fees
- Competitive pricing: semaglutide microdose from $167/month, tirzepatide from $180/month (promotional)
- Unlimited provider messaging for 12 months included; video consults available
- Founded by Bryan Johnson and Kate Tolo; clinical lead Dr. Carl Seger, M.D. (preventive/longevity medicine)
Where it loses points
- Microdose framing uses sub-clinical doses — lower weight-loss efficacy than standard GLP-1 protocols
- Quarterly commitment only — 3-month minimum, paid upfront ($501–$540/quarter); no monthly flexibility
- State availability not publicly listed; 'eligible U.S. states' with no specific state list
- Labs not included; baseline bloodwork protocol not disclosed on any public page
- Compounding pharmacy not named; no 503A/503B accreditation details disclosed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.